| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Satsuma Pharmaceuticals Inc. | STS101 - (ASCEND) | Migraine | PDUFA | Intranasal | Neurology | |
| Satsuma Pharmaceuticals Inc. | STS101 - (SUMMIT) | Migraine | Phase 3 | Intranasal | Neurology | |
| Savara Inc. | MOLBREEVI (Molgradex) - (IMPALA-2) | Autoimmune pulmonary alveolar proteinosis (aPAP) | BLA Filing | Ongoing | Inhalation | Respiratory |
| Savara Inc. | AeroVanc - AVAIL | MRSA in cystic fibrosis | Phase 3 | Trial Discontinued | Inhalation | Antibiotic |
| Savara Inc. | Aironite - INDIE | Heart failure with preserved ejection fraction (HFpEF) | Phase 2 | Trial Discontinued | Intravenous | Cardiology |
| Savara Inc. | Molgradex - ENCORE | Nontuberculous mycobacterial (NTM) lung infection with cystic fibrosis (CF) | Phase 2a | Trial Discontinued | Inhalation | Respiratory |
| Savara Inc. | Molgradex - OPTIMA | Nontuberculous mycobacteria (NTM) | Phase 2a | Trial Completed | Inhalation | Antibiotic |
| Savara Inc. | Molgradex - ENCORE | Nontuberculous mycobacterial (NTM) lung infection with cystic fibrosis (CF) | Phase 2a | Trial Discontinued | Inhalation | Respiratory |